Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Background: Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim: To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. Material and Methods: Sixty-one patients with HCV genotype 1...

Full description

Bibliographic Details
Main Authors: Seyfettin Köklü, Iftihar Köksal, Ulus Salih Akarca, Ayhan Balkan, Rahmet Güner, Aylin Demirezen, Memduh Sahin, Sila Akhan, Reşat Ozaras, Ramazan Idilman
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Annals of Hepatology
Subjects:
Chronic C hepatitis
Daclatasvir
Asunaprevir
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119303631

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119303631

Similar Items